A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VSA012 After Single Ascending Doses in Healthy Volunteers
Latest Information Update: 07 May 2026
At a glance
- Drugs VSA 012 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bisirna Therapeutics (Suzhou); Visirna Therapeutics
Most Recent Events
- 04 May 2026 Protocol has been amended to include three new arms (Experimental: cohort3, Experimental: Cohort4 and Experimental: cohort5) , it has changed from 2 to 5.
- 04 May 2026 Planned End Date changed from 1 Mar 2026 to 1 Jun 2027.
- 04 May 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Aug 2026.